Symptom-modifying slow-acting drugs in the treatment of osteoarthritis: from molecule to clinical effect (a pharmacologist's view)
The paper systematizes data on the pharmacokinetics, molecular and cellular mechanisms of action of chondroprotectors (CPs), by using chondroitin sulfate (CS) and glucosamine (GA) as an example. It presents current ideas about the mechanisms of their absorption and penetration into the joint tissues...
Saved in:
| Main Author: | A. S. Dukhanin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2018-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/830 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacotherapy of pain in musculoskeletal diseases: evolution and revolution of views
by: O. A. Shavlovskaya, et al.
Published: (2022-08-01) -
Symptomatic delayed-acting drugs (SYSADOA): new applications
by: A. M. Lila, et al.
Published: (2022-05-01) -
From misconceptions to reasonable osteoarthritis patients therapy
by: O. A. Shavlovskaya, et al.
Published: (2023-07-01) -
Cardiovascular safety and efficacy of the combined symptomatic slow-acting drug glucosamine and chondroitin sulfate in patients with gonarthrosis
by: A. P. Rebrov, et al.
Published: (2016-06-01) -
Treatment in patients with osteoarthritis at different sites: Place of slow-acting drugs
by: N. V. Chichasova, et al.
Published: (2015-06-01)